← Leaderboards
Bruce E. Johnson
Dana-Farber Cancer Inst
$13,594,149
Attributed
$15,248,512
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.7M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$36,602,912 · 12
By mechanism
U2C$14,880,981 · 3
P50$11,385,000 · 1
P20$5,119,015 · 1
R01$3,856,117 · 1
R33$876,508 · 1
P30$485,291 · 3
Top collaborators
- Pasi A Janne5 shared
- Aviv Regev4 shared
- Todd R. Golub1 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Gabriel K. Griffin$806,256
- Brian Matthew Wolpin$8,665,523
- Toni Choueiri$2,782,193
- Ursula Anne Matulonis$3,602,637
- Alexander H. Stegh$12,620,634
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistanceGenomicsBaseMalignant NeoplasmsImmunotherapyMalignant Neoplasm Of LungTumorLeadMutationMemberPharmaceutical PreparationsEpidermal Growth Factor ReceptorInstitutionBiopsyCancer CenterClinical ResearchPathogenesisProgramsErlotinibCollaborationsResistance MechanismGefitinibPreclinical StudyHistologic
Grant awards (55)
Program 34: Lung Cancer$40,758
P30 · FY2024 · CA · contact PI
Biospecimen Unit$1,241,085
U2C · FY2023 · CA · contact PI
Program 34: Lung Cancer$42,116
P30 · FY2023 · CA · contact PI
Program 34: Lung Cancer$42,116
P30 · FY2022 · CA · contact PI
The Cellular Geography of Therapeutic Resistance in Cancer$2,397,774
U2C · FY2021 · CA · contact PI
Biospecimen Unit$575,561
U2C · FY2021 · CA · contact PI
Administrative Core$403,118
U2C · FY2021 · CA · contact PI
Program 34: Lung Cancer$71,074
P30 · FY2021 · CA · contact PI
The Cellular Geography of Therapeutic Resistance in Cancer$2,524,824
U2C · FY2020 · CA · contact PI
Biospecimen Unit$607,324
U2C · FY2020 · CA · contact PI
Administrative Core$434,879
U2C · FY2020 · CA · contact PI
Program 34: Lung Cancer$70,961
P30 · FY2020 · CA · contact PI
Program 34: Lung Cancer$2,948
P30 · FY2020 · CA · contact PI
The Cellular Geography of Therapeutic Resistance in Cancer$2,524,826
U2C · FY2019 · CA · contact PI
Biospecimen Unit$607,324
U2C · FY2019 · CA · contact PI
Administrative Core$434,881
U2C · FY2019 · CA · contact PI
Program 34: Lung Cancer$69,331
P30 · FY2019 · CA · contact PI
Program 34: Lung Cancer$6,167
P30 · FY2019 · CA · contact PI
The Cellular Geography of Therapeutic Resistance in Cancer$2,521,976
U2C · FY2018 · CA · contact PI
Biospecimen Unit$607,409
U2C · FY2018 · CA · contact PI
Clinical implementation of single cell tumor transcriptome analysis$438,253
R33 · FY2018 · CA
Program 34: Lung Cancer$72,325
P30 · FY2018 · CA · contact PI
Program 34: Lung Cancer$11,430
P30 · FY2018 · CA · contact PI
Program 34: Lung Cancer$5,848
P30 · FY2018 · CA · contact PI
Program 34: Lung Cancer$5,123
P30 · FY2018 · CA · contact PI
Program 34: Lung Cancer$3,833
P30 · FY2018 · CA · contact PI
Program 34: Lung Cancer$1,602
P30 · FY2018 · CA · contact PI
Clinical implementation of single cell tumor transcriptome analysis$438,255
R33 · FY2017 · CA
Program 34: Lung Cancer$39,659
P30 · FY2017 · CA · contact PI
EGFR Mutations in Non-Small Cell Lung Cancer$495,346
R01 · FY2016 · CA · contact PI
EGFR Mutations in Non-Small Cell Lung Cancer$495,346
R01 · FY2015 · CA · contact PI
EGFR Mutations in Non-Small Cell Lung Cancer$480,485
R01 · FY2014 · CA · contact PI
EGFR Mutations in Non-Small Cell Lung Cancer$465,626
R01 · FY2013 · CA · contact PI
Dana-Farber/Harvard Cancer Center SPORE in Lung Cancer$2,300,000
P50 · FY2012 · CA · contact PI
EGFR Mutations in Non-Small Cell Lung Cancer$495,415
R01 · FY2012 · CA · contact PI
Dana-Farber/Harvard Cancer Center SPORE in Lung Cancer$2,185,000
P50 · FY2011 · CA · contact PI
Dana-Farber/Harvard Cancer Center SPORE in Lung Cancer$2,300,000
P50 · FY2010 · CA · contact PI
Dana-Farber/Harvard Cancer Center SPORE in Lung Cancer$2,300,000
P50 · FY2009 · CA · contact PI
EGFR Mutations in non-Small Cell Lung Cancer$278,041
R01 · FY2009 · CA · contact PI
Dana-Farber/Harvard Cancer Center SPORE in Lung Cancer$2,300,000
P50 · FY2008 · CA · contact PI
EGFR Mutations in non-Small Cell Lung Cancer$279,269
R01 · FY2008 · CA · contact PI
SPORE in Lung Cancer$1,002,096
P20 · FY2007 · CA · contact PI
EGFR Mutations in non-Small Cell Lung Cancer$280,463
R01 · FY2007 · CA · contact PI
SPORE in Lung Cancer$1,032,025
P20 · FY2006 · CA · contact PI
EGFR Mutations in non-Small Cell Lung Cancer$289,347
R01 · FY2006 · CA · contact PI
SPORE in Lung Cancer$1,056,861
P20 · FY2005 · CA
EGFR Mutations in non-Small Cell Lung Cancer$296,779
R01 · FY2005 · CA
SPORE in Lung Cancer$1,028,033
P20 · FY2004 · CA
SPORE in Lung Cancer$1,000,000
P20 · FY2003 · CA
TECHNIQUE FOR DETERMINATION OF CARDIAC OUTPUT DURING HEAVY EXERCISE$0
M01 · FY2002 · RR
PULMONARY SYSTEM LIMITATIONS DURING EXERCISE IN CHRONIC HEART FAILURE$0
M01 · FY2002 · RR
TECHNIQUE FOR DETERMINATION OF CARDIAC OUTPUT DURING HEAVY EXERCISE$0
M01 · FY2001 · RR
PULMONARY SYSTEM LIMITATIONS DURING EXERCISE IN CHRONIC HEART FAILURE$0
M01 · FY2001 · RR
TECHNIQUE FOR DETERMINATION OF CARDIAC OUTPUT DURING HEAVY EXERCISE$0
M01 · FY2000 · RR
PULMONARY SYSTEM LIMITATIONS DURING EXERCISE IN CHRONIC HEART FAILURE$0
M01 · FY2000 · RR